GGrantIndex
Sort

172,184 grants matching inflammation

Autophagy Modulators as Novel Broad-Spectrum Anti-Infective Agents

$7,381,267
Herbert W Virgin · Ut Southwestern Medical Center · U19 · FY2020 · AI

Autophagy Modulators as Novel Broad-Spectrum Anti-Infective Agents

$7,381,267
Herbert W Virgin · Ut Southwestern Medical Center · U19 · FY2023 · AI

Autophagy Modulators as Novel Broad-Spectrum Anti-Infective Agents

$7,381,267
Herbert W Virgin · Ut Southwestern Medical Center · U19 · FY2022 · AI

Autophagy Modulators as Novel Broad-Spectrum Anti-Infective Agents

$7,381,267
Beth C Levine · Ut Southwestern Medical Center · U19 · FY2019 · AI

Autophagy Modulators as Novel Broad-Spectrum Anti-Infective Agents

$7,381,267
Herbert W Virgin · Ut Southwestern Medical Center · U19 · FY2021 · AI

EXTREME LONGEVITY FAMILY STUDY

$7,376,403
Michael A Province · Washington University · U01 · FY2010 · AG

IGF::OT::IGFEMMES NEIS-V

$7,315,897
Keri Hammel · The Emmes Company, Llc · N01 · FY2021 · OD

Inflammation and the Host Response to Injury

$7,310,756
Massachusetts General Hospital · U54 · FY2002 · GM

General Clinical Research Center

$7,246,894
Richard D Krugman · University Of Colorado Denver · M01 · FY2007 · RR

IGF::OT::IGFEMMES NEIS-V

$7,243,461
Keri Hammel · The Emmes Company, Llc · N01 · FY2018 · OD

Study in Parkinson Disease of Exercise Phase 3 Clinical Trial: SPARX3

$7,226,355
Daniel M Corcos · Northwestern University At Chicago · U01 · FY2023 · NS

IGF::OT::IGFEMMES NEIS-V

$7,217,805
Keri Hammel · The Emmes Company, Llc · N01 · FY2019 · OD

IGF::OT::IGFEMMES NEIS-V

$7,212,964
Keri Hammel · The Emmes Company, Llc · N01 · FY2020 · OD

Clarifying the Optimal Application of SLT Therapy (COAST) Trial

$7,182,740
Stephen R Wisniewski · University Of Pittsburgh At Pittsburgh · UG1 · FY2024 · EY

Study in Parkinson Disease of Exercise Phase 3 Clinical Trial: SPARX3

$7,159,125
Daniel M Corcos · Northwestern University At Chicago · U01 · FY2020 · NS

The Emory Healthy Brain Study: Discovering Predictive Biomarkers for Alzheimer's Disease

$7,138,053
James J Lah · Emory University · R01 · FY2022 · AG

The Emory Healthy Brain Study: Discovering Predictive Biomarkers for Alzheimer's Disease

$7,125,379
James J Lah · Emory University · R01 · FY2021 · AG

GENERAL CLINICAL RESEARCH CENTER

$7,120,143
Richard D Krugman · University Of Colorado Denver · M01 · FY2006 · RR

SPIROMICS II: Biological underpinnings of COPD heterogeneity and progression

$7,089,002
Prescott G Woodruff · University Of California, San Francisco · U01 · FY2018 · HL

Sensory Phenotyping to Enhance Neuropathic Pain Drug Development

$7,081,684
Roy Freeman · Beth Israel Deaconess Medical Center · UH3 · FY2025 · NS

Prenatal Diagnosis Of Congenital Anomalies

$7,066,657
Roberto Romero · Eunice Kennedy Shriver National Institute Of Child Health & Human Development · ZIA · FY2019 · HD

Dysfunctional lipid metabolism and peroxidation in chronic pain and neurodegeneration

$7,042,784
Christopher Ramsden · National Institute On Aging · ZIA · FY2022 · AG

The Emory Healthy Brain Study: Discovering Predictive Biomarkers for Alzheimer's Disease

$7,011,679
James J Lah · Emory University · R01 · FY2023 · AG

The Emory Healthy Brain Study: Discovering Predictive Biomarkers for Alzheimer's Disease

$7,011,679
James J Lah · Emory University · R01 · FY2024 · AG

National Social Life, Health, and Aging Project: Round 5

$6,976,331
Linda J Waite · National Opinion Research Center · R01 · FY2025 · AG